Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial

Lucia Romani, Michael Marks, Oliver Sokana, Titus Nasi, Bakaai Kamoriki, Billie Cordell, Handan Wand, Margot J Whitfeld, Daniel Engelman, Anthony W Solomon, John M Kaldor, Andrew C Steer

Summary

Background In small community-based trials, mass drug administration of ivermectin has been shown to substantially decrease the prevalence of both scabies and secondary impetigo; however, their effect at large scale is untested. Additionally, combined mass administration of drugs for two or more neglected diseases has potential practical advantages, but efficacy of potential combinations should be confirmed.

Methods The azithromycin ivermectin mass drug administration (AIM) trial was a prospective, single-arm, before-and-after, community intervention study to assess the efficacy of mass drug administration of ivermectin for scabies and impetigo, with coadministration of azithromycin for trachoma. Mass drug administration was offered to the entire population of Choiseul Province, Solomon Islands, and of this population we randomly selected two sets of ten sentinel villages for monitoring, one at baseline and the other at 12 months. Participants were offered a single dose of 20 mg/kg azithromycin, using weight-based bands. Children weighing less than 12·5 kg received azithromycin oral suspension (20 mg/kg), and infants younger than 6 months received topical 1% tetracycline ointment. For ivermectin, participants were offered two doses of oral ivermectin 200 μg/kg 7–14 days apart using weight-based bands, or 5% permethrin cream 7–14 days apart if ivermectin was contraindicated. Our study had the primary outcomes of safety and feasibility of large-scale mass coadministration of oral ivermectin and azithromycin, which have been previously reported. We report here the prevalence of scabies and impetigo in residents of the ten baseline villages compared with those in the ten-12-month villages, as measured by examination of the skin, which was a secondary outcome of the trial. Further outcomes were comparison of the number of all-cause outpatient attendances at government clinics in Choiseul Province at various timepoints before and after mass drug administration. The trial was registered with the Australian and New Zealand Trials Registry (ACTRN12615001199505).

Findings During September, 2015, over 4 weeks, 26 188 people (99·3% of the estimated population of Choiseul [n=26 372] as determined at the 2009 census) were treated. At baseline, 1399 (84·2%) of 1662 people living in the first ten villages had their skin examined, of whom 261 (18·7%) had scabies and 347 (24·8%) had impetigo. At 12 months after mass drug administration, 1261 (77·6%) of 1625 people in the second set of ten villages had their skin examined, of whom 29 (2·3%) had scabies (relative reduction 88%, 95% CI 76·5–99·3) and 81 (6·4%) had impetigo (relative reduction 74%, 63·4–84·7). In the 3 months after mass drug administration, 10 614 attended outpatient clinics for any reason compared with 16 602 in the 3 months before administration (decrease of 36·1%, 95% CI 34·7–37·6), and during this period attendance for skin sores, boils, and abscesses decreased by 50·9% (95% CI 48·6–53·1).

Interpretation Ivermectin-based mass drug administration can be scaled to a population of over 25 000 with high efficacy and this level of efficacy can be achieved when mass drug administration for scabies is integrated with mass drug administration of azithromycin for trachoma. These findings will contribute to development of population-level control strategies. Further research is needed to assess durability and scalability of mass drug administration in larger, non-island populations, and to assess its effect on the severe bacterial complications of scabies.

Funding International Trachoma Initiative, Murdoch Children’s Research Institute, Scobie and Claire Mackinnon Trust, and the Welcome Trust.

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction Scabies is a parasitic skin disease that affects an estimated 200 million people worldwide.1 It is endemic in many tropical developing countries, especially in rural and remote communities where access to treatment is lacking and domestic overcrowding is common.2 Scabies causes skin inflammation with itch that is frequently severe, and often associated with bacterial skin infection caused by Staphylococcus aureus and Streptococcus pyogenes (impetigo).2 This infection can in turn lead to severe complications including septicaemia and post-streptococcal glomerulonephritis, and

Lancet Infect Dis 2019; 19: 510–18
Published Online April 4, 2019
http://dx.doi.org/10.1016/S1473-3099(18)30790-4
See Comment page 454
The Kirby Institute, UNSW, Sydney, NSW, Australia (L Romani PhD, H Wand PhD); Prof J M Kaldor PhD); St Vincent’s Hospital, Sydney, NSW, Australia (M Marks PhD, A W Solomon); Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK (M Marks PhD, A W Solomon FRCP); Hospital for Tropical Diseases, London, UK (M Marks, A W Solomon); Ministry of Health and Medical Services, Honiara, Solomon Islands (O Sokana MPH, T Nasi MCH, B Kamoriki); and Centre for International Child Health, University of Melbourne, Melbourne, VIC, Australia (D Engelman, Prof A C Steer)
Correspondence to: Prof Andrew C Steer, Murdoch Children’s Research Institute, Parkville, Melbourne, VIC 3052, andrew.steer@rch.org.au

Articles
increasing evidence supports a causal link to acute rheumatic fever and rheumatic heart disease.

By contrast, the strategy of mass drug administration, involving treatment of entire communities, has been known in small community-based trials to substantially decrease the prevalence of both scabies and secondary impetigo. Several small, single-arm studies suggested the effectiveness of mass drug administration using topical permethrin or oral ivermectin, with ivermectin widely used in lymphatic filariasis and onchocerciasis elimination programmes. A report from Zanzibar, Tanzania, showed a decrease of over 68% in prescriptions of treatments for scabies after five annual rounds of mass drug administration with ivermectin and albendazole (given for lymphatic filariasis) in a population of over 1 million people. The first comparative trial of mass drug administration for scabies was the skin health intervention Fiji trial (SHIFT), which found that ivermectin-based mass drug administration decreased the prevalence of scabies by 94% 1 year after the intervention, and was superior to both mass drug administration of topical permethrin and standard care. However, the generalisability of this finding was restricted by the study’s location in small, isolated populations (the ivermectin mass drug administration group had a baseline population of 716 people) and the authors recognised a need for a larger scale evaluation.

High prevalences of scabies have been reported in the Pacific region, including in a population-based survey in Western Province, Solomon Islands, where the all-ages prevalence of scabies was 19.2% and impetigo was 32.7% in 2014. Other neglected tropical diseases, including trachoma, are also public health problems in the Solomon Islands. A national programme to eliminate trachoma was planned in all ten provinces that comprise the Solomon Islands and commenced in 2014, using the WHO SAFE (ie, surgery for trichiasis, antibiotics, facial cleanliness, and environmental improvement) strategy, which includes mass drug administration with azithromycin.

We planned to use the azithromycin mass drug administration infrastructure to study the codelivery of ivermectin-based mass drug administration. In the azithromycin ivermectin mass drug administration (AIM) trial, we had the primary outcomes of safety and feasibility of large-scale mass co-administration of ivermectin and azithromycin and we recently reported these outcomes, in particular the absence of serious adverse events, in a study population of over 25 000 people. The secondary outcome focused on the efficacy of the intervention against community prevalence of scabies and impetigo, which we report in this Article.
Methods

Study setting and population

This prospective, single-arm, before-and-after, community intervention trial was undertaken in Choiseul Province of the Solomon Islands. The Solomon Islands is an island nation in the south Pacific with an estimated population of approximately 580,000 people in 2016, living largely in rural and remote settings, and has a Human Development Index rank of 156 of 188. The province of Choiseul occupies the entirety of one large and several smaller islands, with a population of 26,372 recorded in the 2009 national census. Health care is provided by 17 nurse aid posts, ten rural health clinics, one area health centre, and one hospital located in the provincial capital, Taro. Based on a 2013 population-based survey that showed a prevalence of active trachoma in children aged 1–9 years above the elimination threshold, Choiseul had been scheduled to receive azithromycin mass drug administration in 2015 through the national eye-health programme. These plans were modified to incorporate coadministration of ivermectin-based mass drug administration for scabies and impetigo.

We selected ten sentinel villages for a baseline skin survey. A full list of settlements on the island with their populations estimated by use of the most recent census was provided by the Ministry of Health and Medical Services. We used simple random sampling to select the sentinel settlements, with the only inclusion criterion of a population of 100–250 people. On the same basis, 1 year after the intervention we randomly selected ten different villages for the skin survey. At both timepoints, all residents of selected villages were invited to participate in the skin survey. Additionally, at 12 months, we randomly selected four of the initially selected sentinel villages and revisited them to evaluate efficacy in paired sites.

All residents of selected sentinel villages were eligible to participate in skin surveys for this study, with no age restrictions, and written informed consent was obtained from adults and from the parents or guardians of children.

The trial was registered with the Australian and New Zealand Trials Registry (ACTRN12615001199505) and approved by the Solomon Islands National Research Ethics Committee (15/33) and the Royal Children’s Hospital Human Research Ethics Committee (35148A). An independent data safety monitoring committee oversaw the trial. Verbal consent was obtained from all individuals to participate in the mass drug administration programme.

Procedures

Teams were assembled from local health staff and trained for both azithromycin-based and ivermectin-based mass drug administration. The AIM study team had extensive preliminary discussions with key stakeholders and followed an established process for the introduction of new community health initiatives in the Solomon Islands. This process included endorsement by the Solomon Islands Ministry of Health and Medical Services, and engagement with the communities involved. Information sheets explaining the study were distributed by trained community nurses and were available to study participants before enrolment.

The study coordinator (LR), who is highly experienced in scabies diagnosis, examined the skin of each participant for scabies and impetigo at both baseline and 12 months. One of two local nurses assisted with electronic data entry of examination findings using Open Data Kit (ODK, Seattle, USA). We used the same clinical diagnostic methods for these diseases as used in previous studies in Fiji and the Solomon Islands. Scabies was defined as pruritic inflammatory papules with a typical anatomical distribution, such as the webs of the fingers, hands, wrists, and ankles, as per integrated management of childhood illnesses guidelines. Examination excluded breasts and genitals, unless requested by participants and then only in a separate, private examination area. Impetigo was defined as papular, pustular, or ulcerative lesions surrounded by erythema. The definition of crusted scabies we used was as previously described.

All outpatient attendances at government clinics in the Solomon Islands are recorded in a standard case register (including patient age, sex, reason for attendance) at the clinic level. Each month, information collected in these registers is required to be transferred electronically via the District Health Information System (DHIS2) to the Solomon Islands Ministry of Health and Medical Services statistics office at the national level. Monthly reporting completeness is the proportion of clinics that submitted a report for that month. Because this proportion varied from month to month, we standardised absolute counts for Choiseul Province by assuming that those clinics that submitted a report were representative of all clinics in the province. We obtained data for the 12 months before and 12 months after the mass drug administration.

The regimen for trachoma antibiotic mass drug administration followed standard WHO guidelines, identical to the regimen used for mass drug administration for trachoma in the rest of the country. Participants were offered a single dose of 20 mg/kg azithromycin, up to a maximum of 1 g, using weight-based bands. Children weighing less than 12.5 kg received azithromycin oral suspension at a dose of 20 mg/kg. Drug administration was directly observed for all participants receiving azithromycin. Infants younger than 6 months received topical 1% tetracycline ointment for administration by a parent or guardian to both eyes twice per day for 6 weeks. A trained study nurse provided instructions to the parents on how to apply tetracycline eye ointment.

For ivermectin-based mass drug administration, participants were offered either two doses of oral ivermectin 200 μg/kg 7–14 days apart using weight-based bands, or if ivermectin was contraindicated (such as...
for pregnant and breastfeeding women and children weighing less than 12·5 kg) they were instead offered two applications of topical 5% permethrin cream 7–14 days apart. Drug administration was directly observed for all participants receiving ivermectin. Participants who were offered permethrin were given the option to have a trained nurse apply the cream in a private room at the clinic or to apply it themselves at home. The first dose of ivermectin or permethrin was administered at the same time as the antibiotic treatment.

Outcomes
The main outcome of the study (a secondary outcome in the original AIM trial) was the prevalence of scabies and impetigo in the ten randomly selected villages at 12 months compared with ten different randomly selected villages at baseline. We chose a new set of villages at 12 months to ensure that our estimates of prevalence were as generalisable as possible to the whole province.

Additional analyses were comparison of the total number of people who attended outpatient clinics for any cause in the 3 months after mass drug administration, not including the month of administration, with the 3 months before mass drug administration. We chose a 3 month period because of the likelihood (as perceived by study investigators) that a clinically meaningful effect of mass drug administration at clinic level would persist for at least this period of time.21 We excluded analysis of data from the month during which mass drug administration was being delivered because the intervention was rolled out over 4 weeks and might have led to heightened clinic activity due to referrals by field teams for incidentally found medical issues. In addition to the 3-month comparisons, we compared attendance at outpatient clinics for any reason the 1 month before and after mass drug administration, the 12 months before and after mass drug administration (not including the administration month), and the 3-month period 12 months before mass drug administration with the 3-month period after mass drug administration.

Furthermore, we also returned to four of the baseline villages and compared the prevalence of scabies and impetigo at 12 months and baseline in these villages using paired analysis.

Statistical analysis
On the basis of 2014 prevalence data from the Solomon Islands and SHIFT data,21 we expected that the overall prevalence of scabies would be approximately 20% at baseline, decreasing to less than 5% after mass drug administration. We estimated that an overall sample size of 1200 individuals would be required at each of the two timepoints, assuming 80% participation and accounting for a 3% village-level correlation coefficient (assuming approximately 30–300 individuals per site at each timepoint). This sample size would allow us to estimate the prevalence at each timepoint with high precision (ie, within 5% or −5% absolute width of the respective CIs), and allow us to detect the difference in prevalence as significant at the 0·05 level when comparing the two timepoints (ie, 20% vs 5%) with 80% power. The statistical test of significance for this comparison, to be applied at the two-sided 0·05 level, was a χ² test that takes into account the sample sizes at both the baseline and 12-month sampling points and accounts for cluster size.22 We calculated absolute (difference between baseline and month 12) and relative reductions (ratio of month 12 to baseline) in prevalence and their 95% CIs on the basis of their respective variances using the binomial distribution.21 We analysed the distribution of scabies and impetigo by demographic factors and calculated adjusted odds ratios (ORs) by fitting a logistic regression model adjusting for sex, age group, and village variables. We analysed clinic data by age group and by 12 communicable disease categories for which data are routinely reported. Clinic presentations were adjusted to monthly reporting completeness across all clinics in Choiseul Province by dividing reported cases by the monthly reporting rate (appendix).

We did all analyses using Stata version 14.2. This trial was registered with the Australian and New Zealand Trials Registry (ACTRN12615001199505).

Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results
In September, 2015, over 4 weeks, 26 188 participants were enrolled, 99·3% of the resident population in the
Choiseul Province based on the 2009 census (n=26 372).16
At baseline, of 1662 people living in the ten sentinel villages (villages A–J), 1399 (84·2%) consented to participate and were examined. 12 months after mass drug administration, in September, 2016, of 1625 people in the second set of sentinel villages (villages K–T), 1261 (77·6%) consented to participate and were examined (figure 1). The sex and age distributions of individuals included in the two samples were similar (tables 1 and 2) The locations of each village chosen, each designated with a letter from A to T, are shown on figure 2. At baseline, 209 (14·9%) of 1399 people in the ten baseline sentinel villages were ineligible to receive ivermectin, of whom 75 (36%) were children weighing less than the required 12·5 kg and 134 (64%) were pregnant or breastfeeding women, and so were offered permethrin.

In the ten baseline sentinel villages (villages A–J), 261 people had scabies (18·7%, 95% CI 16·7–20·8; table 3). Prevalence was highest in children aged 5–9 years (34·0%, 95% CI 28·1–40·2; adjusted OR 4·7, 95% CI 3·0–7·2, when compared with participants aged 35 years and older; appendix). Scabies was more common in girls and women than boys and men (adjusted OR 1·3, 95% CI 1·0–1·7; appendix). Scabies was observed in all ten baseline sentinel villages, with prevalences ranging from 15·1% to 31·5% (appendix). 347 people had impetigo (24·8%, 95% CI 22·6–27·1; table 3), and prevalence was highest among children aged 5–9 years (prevalence 46·4%, 95% CI 40·1–52·8; adjusted OR 7·8, 95% CI 5·1–12·0; appendix).

At 12 months, in the second set of ten sentinel villages (villages K–T), 29 people had scabies (2·3%, 95% CI

| Baseline population (n=1399) | Month 12 population (n=1261) |
|-----------------------------|-------------------------------|
| **Overall**                  | **Overall**                   |
| Sex                         | Sex                           |
| Male                        | Male                          |
| Female                      | Female                        |
| Age, years                  | Age, years                    |
| Median                      | Median                        |
| <5                          | <5                            |
| 5–9                         | 5–9                           |
| 10–14                       | 10–14                         |
| 15–24                       | 15–24                         |
| ≥35                         | ≥35                           |
| Village level enrolment     | Village level enrolment       |
| Village A n=209             | Village K n=129               |
| Participants 178 (12·7%)    | Participants 108 (8·6%)       |
| Village B n=147             | Village L n=186               |
| Participants 114 (8·1%)     | Participants 95 (7·5%)        |
| Village C n=118             | Village M n=199               |
| Participants 70 (5·0%)      | Participants 122 (9·7%)       |
| Village D n=134             | Village N n=121               |
| Participants 157 (11·2%)    | Participants 93 (7·4%)        |
| Village E n=109             | Village O n=165               |
| Participants 106 (7·6%)     | Participants 156 (12·4%)      |
| Village F n=121             | Village P n=118               |
| Participants 106 (7·6%)     | Participants 108 (8·6%)       |
| Village G n=219             | Village Q n=132               |
| Participants 162 (11·6%)    | Participants 111 (8·8%)       |
| Village H n=102             | Village R n=251               |
| Participants 88 (6·3%)      | Participants 229 (18·1%)      |
| Village I* n=118            | Village S n=109               |
| Participants 54 (3·9%)      | Participants 70 (5·5%)        |
| Village J* n=260            | Village T n=215               |
| Participants 299 (21·4%)    | Participants 169 (13·4%)      |

Table 1: Characteristics of participants in ten baseline sentinel villages

| Table 2: Characteristics of participants in ten 12-month sentinel villages |

Data are median (IQR) or n (%) as a proportion of the study population. *Residents of villages I and J were seen together because they were all attending a social gathering at the time of examination, combined enrolment for villages I and J: 353 (93·4%) of 378.

Table 2: Characteristics of participants in ten 12-month sentinel villages
1·6–3·3), corresponding to a relative reduction in prevalence of 88% (95% CI 76·5–99·3) from baseline (table 3). 81 people had impetigo (prevalence of 6·4%, 5·2–8·0; relative reduction of 74%, 95% CI 63·4–84·7; table 3). Full prevalence data for scabies and impetigo by age group and village at 12 months are in the appendix.

Among the four randomly selected villages examined at both baseline and 12 months, (villages A, B, C, and D) the decrease in prevalence of scabies and impetigo followed a similar pattern to that observed when comparing the two distinct sets of sentinel villages. Overall, scabies prevalence decreased from 19·5% (101 of 519) to 1·3% (five of 375; relative reduction of 93·3%, 95% CI 74·5–100) and impetigo from 22·4% (116 of 519) to 5·1% (19 of 375; relative reduction of 77·2%, 95% CI 58·0–96·0; appendix). We observed no cases of crusted scabies among participants.

In October to December, 2015, the 3 months after mass drug administration, 10614 people attended outpatient clinics in Choiseul Province for any reason compared with 16602 in June to August, 2015, the 3 months before mass drug administration (table 4), corresponding to a decrease of 36·1% (95% CI 34·7–37·6). We observed a similar decrease when we compared attendance in the 1 month periods before (August, 2015, n=6269) and after (October, 2015, n=3624) mass drug administration (decrease of 42·2%, 95% CI 41·0–43·4). All-cause outpatient attendance decreased from 19789 in October to December, 2014, to 10614 in October to December, 2015, showing a decrease of 46·4% (95% CI 45·7–47·1). 68471 people attended outpatient clinics during the 12 months before mass drug administration (September, 2014, to August, 2015) and 59162 attended in the 12 months after administration (October, 2015, to September, 2016, a decrease of 13·6% (95% CI 13·3–13·9).

The overall decrease in outpatient attendance for reported communicable diseases from the 3 months before to the 3 months after mass drug administration was 40·7% (95% CI 39·6–41·8, table 5). A larger decrease was observed for presentations categorised as skin sores, boils, and abscesses (50·9%, 95% CI 48·6–53·1) than for any other presentation of disease. When comparing the 3-month period 12 months before mass drug administration (October to December, 2014) with the 3-month period after (October to December, 2015), we observed a large decrease in attendance for communicable diseases (53·8%, 95% CI 54·8–56·7; appendix).

**Discussion**

We found the relative reduction in the prevalence of scabies was 88% compared with 94% in SHIFT,1 and the decrease in the prevalence of impetigo was substantial in both AIM and SHIFT (74% AIM vs 67% SHIFT). Hence, the results of the AIM trial reported here show that ivermectin-based mass drug administration can be scaled to a population of over 25 000 with a similar efficacy as in small island-based trial settings and that this level of efficacy can be achieved when mass drug administration for scabies is integrated with azithromycin mass drug administration for trachoma.

Given the absence of any known biological effect of ivermectin on bacterial organisms that cause skin infections, the substantial decrease in the prevalence of impetigo observed in AIM and SHIFT strongly support the hypothesis that scabies is an important causal factor for impetigo. The decrease in impetigo burden here
Table 5: Outpatient clinic attendance for communicable diseases syndromes in the 3 months before and after mass drug administration

| Presentation                          | June-August, 2015 | October-December, 2015 | Reduction in presentations (%) |
|--------------------------------------|-------------------|------------------------|-------------------------------|
| Acute respiratory infection          | 4185              | 2672                   | 1512 (36%)                    |
| Skin sores, boils, and abscesses     | 1931              | 949                    | 982 (51%)                     |
| Acute ear infection                  | 578               | 428                    | 150 (26%)                     |
| Watery diarrhoea                     | 352               | 219                    | 133 (38%)                     |
| Red eye                              | 239               | 161                    | 78 (33%)                      |
| Chronic ear infection                | 130               | 59                     | 71 (55%)                      |
| Yaws                                 | 114               | 15                     | 99 (87%)                      |
| Fungal skin infection                | 107               | 54                     | 53 (50%)                      |
| Bloody diarrhoea                     | 58                | 14                     | 44 (76%)                      |
| Scabies                              | 26                | 8                      | 18 (69%)                      |
| Neonatal bacterial infection         | 4                 | 0                      | 4 (100%)                      |
| Total                                | 7723              | 4578                   | 3144 (41%)                    |

Data are n and n (% reduction).

Table 5: Outpatient clinic attendance for communicable diseases syndromes in the 3 months before and after mass drug administration

exceeded estimates of the population-attributable risk of impetigo due to scabies in previous studies in the Pacific Islands. The slightly greater decrease in prevalence of impetigo in AIM than in SHIFT, combined with the known activity of azithromycin against both *Staphylococcus aureus* and *Streptococcus pyogenes*, raises the possibility that azithromycin mass drug administration might have had an additional effect on the prevalence of impetigo beyond that of ivermectin-based mass drug administration alone. However, a community-based trial in the Solomon Islands in 2016–17 comparing ivermectin mass drug administration with azithromycin mass drug administration found no difference in the decrease in prevalence of impetigo between the two groups at 12 months after the intervention (relative reduction 75% vs 73%; *p*=0.49).26

The AIM trial has shown that integration of mass drug administration for control of scabies and trachoma is feasible. However, other than a previous study in Zanzibar,27 few assessments of the effect of mass drug administration containing ivermectin for lymphatic filariasis and onchocerciasis on other neglected tropical diseases exist.27 Formal assessments of the effect of these programmes on scabies and other neglected tropical diseases, such as strongyloidiasis, would be of value in fully characterising the benefits of ivermectin mass drug administration, and the roll-out of triple therapy for control of lymphatic filariasis (ivermectin, diethylcarbamazine, and albendazole) provides a crucial opportunity to assess the effect of this regimen on scabies.28 The importance of making permethrin available for children and others who are contraindicated for ivermectin, as done in this study, needs to be assessed in these other mass drug administration programmes.

We observed a substantial effect of ivermectin and azithromycin mass drug administration on attendance at outpatient clinics, including attendance for skin sores, boils, and skin abscesses, yaws, acute respiratory infections, and diarrhoeal disease. These broader health benefits have been documented previously after mass drug administration of azithromycin for trachoma, including as documented in randomised trials that have found a decrease in overall mortality in young children. Although the effect on acute respiratory infections and diarrhoeal disease observed in AIM is probably associated with azithromycin alone, the effect on attendance at outpatient clinics for bacterial skin infection might have been driven by both ivermectin and azithromycin.

To inform development of public health policies for effective scabies control, several outstanding research questions associated with implementation of mass drug administration for scabies exist, in addition to those associated with scalability and integration. These questions include the effect of mass drug administration on the complications of scabies and impetigo, including severe skin and soft tissue infections, sepsis due to *S aureus* and *S pyogenes*, glomerulonephritis, and rheumatic fever. Monitoring of resistance in bacteria after azithromycin mass drug administration and in parasites after ivermectin mass drug administration will be necessary to mitigate any unintended consequence of large-scale control programmes. Although small targeted studies might be necessary to answer questions about optimal ivermectin dosing, implementation research alongside large-scale roll-out of mass drug administration could be of use to assess the effect of mass drug administration on complications of scabies and impetigo, cost-effectiveness, community acceptability, staff training, and distribution logistics.

Our study had several limitations. Our study was non-randomised, employing a pragmatic before-and-after design appropriate for assessment of the effect of the intervention when delivered in such a large-scale (province-wide) setting, so we cannot say with certainty that factors other than the intervention did not influence our findings. Nevertheless, we are unaware of any other changes over the study period that could have accounted for a decrease in the prevalence of scabies and impetigo of the observed magnitude. With demographic characteristics of the population samples at the two timepoints being very similar, the difference in non-participation at 12 months (22-4%) versus baseline (15-8%) is unlikely to have influenced the findings. We chose ten distinct villages at baseline and 12 months for assessment to eliminate bias that might have been introduced through the presence of the study team. The additional paired analysis of the four villages seen at both baseline and 12 months supports our overall efficacy findings.

In the AIM trial, we offered two doses of ivermectin as part of mass drug administration, whereas in SHIFT a second dose was only provided to those who had clinical scabies because the SHIFT study team was able to screen all individuals within the small study population.
Articles

(n=716). Although some experts suggest that the use of environmental measures might play a role in decreasing reinfestation, we found that mass drug administration alone has high efficacy in decreasing community prevalence of scabies and impetigo. Because a second dose of ivermectin adds complexity and cost to a programme of mass drug administration, studies are ongoing to determine whether the same benefit can be achieved with a single dose of ivermectin for scabies control in highly endemic settings (ACTRN12618001086257 and ACTRN12617000738325). Finally, the data available to us for outpatient presentations were generated through routine reporting, which might have led to under-reporting of specific diseases, but the conditions for reporting were the same in the periods before and after the intervention. Front-line clinicians and health-informatics staff were not made aware in advance that the number of people attending clinics was being collected as part of this research.

In the AIM trial, ivermectin plus antibiotic mass drug administration was highly effective at decreasing scabies and impetigo prevalence at 12 months after the intervention in a population of over 25 000 people in a province in the Solomon Islands. Other substantial short-term health benefits were observed, with notable decreases in all-cause outpatient clinic attendance and presentations for multiple communicable diseases. Scabies was designated by WHO as a neglected tropical disease in April, 2017, and countries are now considering how they will seek to control the disease within a public health framework. The efficacy data presented here support large-scale implementation of ivermectin-based mass drug administration for control of scabies in areas where scabies is identified as a public health priority. Operational research should be undertaken alongside on-going interventions, to assess durability in the decrease of scabies and impetigo and the effect of mass drug administration on the complications of scabies and impetigo, cost-effectiveness, and acceptability.

Contributors
All authors contributed substantially to the design of the study, LR was the primary coordinator of data collection, data analysis, and primary author of the manuscript. All authors contributed to the writing of the manuscript and read and approved the final version. MM coordinated the primary coordinator of data collection, data analysis, and manuscript writing, and vouch for the integrity and completeness of the data and analyses. Declaration of interests
We declare no competing interests.

Acknowledgments
JMK, ACS, and DE were supported by Australian National Health and Medical Research Council Fellowships. ACS is also supported by the National Heart Foundation of Australia. MM is supported by the Wellcome Trust (020807) and the UK National Institute of Health Research. AWS was supported by the Wellcome Trust (098521). We thank Daniel Mason for his assistance in preparing the trial. The authors alone are responsible for the views expressed in this Article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. The study was funded by the International Trachoma Initiative; the Murdoch Children’s Research Institute, Australia; the Scobie and Claire Mackinnon Trust, Australia; and the Wellcome Trust. Ivermectin was provided at a reduced cost by Merck Sharp & Dohme, Australia. Azithromycin was provided directly to the Solomon Islands Ministry of Health and Medical Services National Trachoma Control Programme by the International Trachoma Initiative. The Solomon Islands Ministry of Health and Medical Services provided paid personnel and office space.

References
1. Karimkhani C, Colombo RA, Drucker AM, et al. The global burden of scabies: a cross-sectional analysis from the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; 17: 1247–54.
2. Heukelbach J, Maziço HD, Ugbomoiko US. Impact of scabies in resource-poor communities. Curr Opin Infect Dis 2013; 26: 127–32.
3. Heukelbach J, Feldmeier H. Scabies. Lancet 2006; 367: 1767–74.
4. Parks T, Smeesters PR, Steer AC. Strepococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis 2012; 25: 145–53.
5. WHO. Report of the tenth meeting of the WHO strategic and technical advisory group for neglected tropical diseases: 29–30 March 2017. Geneva. Geneva: Geneva: World Health Organisation, 2017. http://www.who.int/neglected_diseases/NTD_STAG_report_2017pdf (accessed March 15, 2019).
6. Mounsey KE, McCarthy JS. Treatment and control of scabies. Curr Opin Infect Dis 2013; 26: 133–39.
7. La Vincente S, Kearns T, Connors C, Cameron S, Carapetis J, Andrews R. Community management of endemic scabies in remote aboriginal communities of northern Australia: low treatment uptake and high ongoing acquisition. PLoS Negl Trop Dis 2009; 3: e444.
8. Kearns TM, Speare R, Cheng AC, et al. Impact of an ivermectin mass drug administration on scabies prevalence in a remote Australian Aboriginal community. PLoS Negl Trop Dis 2015; 9: e0004151.
9. Romani L, Whitley MF, Korovueta J, et al. Mass drug administration for scabies control in a population with endemic disease. N Engl J Med 2015; 373: 2305–13.
10. Taplin D, Porcelain SL, Meinking TL, et al. Community control of scabies: a model based on use of permethrin cream. Lancet 1991; 337: 1016–18.
11. Evans DS, Alphonsus K, Umaru J, et al. Status of onchocerciasis transmission after more than a decade of mass drug administration for onchocerciasis and lymphatic filariasis elimination in central Nigerian challenges in coordinating the stop MDA decision. PLoS Negl Trop Dis 2014; 8: e3113.
12. Mohammed KA, Deb RM, Stanton MC, Molyneux DH. Soil transmitted helminths and scabies in Zanzibar, Tanzania following mass drug administration for lymphatic filariasis—a rapid assessment methodology to assess impact. Parasit Vectors 2012; 5: 299.
13. Mason DS, Marks M, Sokana O, et al. The prevalence of scabies and impetigo in the Solomon Islands: a population-based survey. PLoS Negl Trop Dis 2016; 10: e0004803.
14. Sokana O, Macleod C, Jack K, et al. Mapping trachoma in the Solomon Islands: results of three baseline population-based prevalence surveys conducted with the global trachoma mapping project. Ophthalmic Epidemiol 2016; 23: 467–74.
15. Romani L, Marks M, Sokana O, et al. Feasibility and safety of mass drug coadministration with azithromycin and ivermectin for the control of neglected tropical diseases: a single-arm intervention trial. Lancet Glob Health 2018; 6: e1132–38.
16. Solomon Islands National Statistical Office: Population and housing census 2009. 2014: 1–98. https://www.stats.gov.sb/statistics/
demographic-statistics/census (accessed March 27, 2019).
17. Human Development reports. Table I. Human Development Index and its components, United Nations Development Programme, 2016. http://hdr.undp.org/en/composite/HDI (accessed March 15, 2019).
18. Steer AC, Tikoduadua LV, Manalac EM, Colquhonu S, Carapetis JR, Macleaner C. Validation of an integrated management of childhood illness algorithm for managing common skin conditions in Fiji. Bull World Health Organ 2009; 87: 173–79.
19. Davis JS, McGlothin S, Tong SY, Walton SF, Currie BJ. A novel clinical grading scale to guide the management of crusted scabies. PLoS Negl Trop Dis 2017; 11: e0004385.
20 Solomon AW, Zondervan M, Kuper H, Buchan JC, Mabey DCW, Foster A. Trachoma control: a guide for programme managers. Geneva: World Health Organization, 2006.
21 Shelby-James TM, Leach AJ, Carapetis JR, Currie BJ, Mathews JD. Impact of single dose azithromycin on group A Streptococci in the upper respiratory tract and skin of Aboriginal children. Pediatr Infect Dis J 2002; 21: 375–80.
22 Hayes R, Moulton L. Cluster randomised trial, 1st edn. Chapman & Hall, CRC Biostatistics Series, 2009.
23 Gardner MJ, Altman DG. Statistics with confidence. London: BMJ publication, 1994: 51–2.
24 Romani L, Korovuva J, Steer AC, et al. Scabies and impetigo prevalence and risk factors in Fiji: a national survey. PLoS Negl Trop Dis 2015; 9: e0003452.
25 Amaya-Tapia G, Agurire-Avalos G, Andrade-Villanueva J, et al. Once-daily azithromycin in the treatment of adult skin and skin-structure infections. J Antimicrob Chemother 1993; 31 (suppl E): 129–35.
26 Marks M, Toloka H, Baker C, et al. Randomised trial of community treatment with azithromycin and ivermectin mass drug administration for control of scabies and impetigo. Clin Infect Dis 2019; 68: 927–33.
27 Martin D, Wiegand R, Goodhew B, Lammie P, Mkocha H, Kasubi M. Impact of ivermectin mass drug administration for lymphatic filariasis on scabies in eight villages in Kongwa District, Tanzania. Am J Trop Med Hyg 2018; 99: 917–19.
28 Fischer PU, King CL, Jacobson JA, Weil GJ. Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa. PLoS Negl Trop Dis 2017; 11: e0005163.
29 Porco TC, Gebre T, Ayele B, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009; 302: 962–68.
30 Coles CL, Levens J, Seidman JC, Mkocha H, Munoz B, West S. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J 2012; 31: 341–46.
31 Fry AM, Jha HC, Lietman TM, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis 2002; 35: 395–402.
32 Keenan JD, Bailey RL, West SK, et al. Azithromycin to reduce childhood mortality in sub-Saharan Africa. N Engl J Med 2018; 378: 1583–92.
33 O’Brien KS, Emerson P, Hooper PJ, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis 2019; 19: e14–23.